2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

2:30PM-4:00PM: Abstract Number: 1850

A Population Based Study of High School Academic Outcomes in Individuals with Childhood-Onset Chronic Rheumatic Diseases in Manitoba, Canada

4M084 ACR Abstract: Pediatric Rheum–Clinical I: Outcomes & Comorbidities (1846–1851)

2:30PM-4:00PM: Abstract Number: 1873

Age- and Cause-Specific Standardized Mortality Ratio of Systemic Lupus Erythematosus Patients in Ontario, Canada over 43 Years (1971-2013)

4M081 ACR Abstract: Edmond L. Dubois, MD Memorial Lecture: SLE–Clinical (1870–1874)

2:30PM-4:00PM: Abstract Number: 1858

An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis

4M086 ACR Abstract: RA–DX, Manifestations, & Outcomes II: DX & Prognosis I (1858–1863)

2:30PM-4:00PM: Abstract Number: 1863

Anti-Cyclic Citrullinated Protein Antibody at Multiple Cutoff Levels and in Combination with Rheumatoid Factor IgM and Serum Calprotectin Is Highly Specific for the Development of Rheumatoid Arthritis within 3 Years

4M086 ACR Abstract: RA–DX, Manifestations, & Outcomes II: DX & Prognosis I (1858–1863)

2:30PM-4:00PM: Abstract Number: 1839

Association of Diet Quality with Overall Fibromyalgia Impact, and Psychosocial and Quality of Life Outcomes in Women with Fibromyalgia

4M082 ACR Abstract: Fibromyalgia & Other Clinical Pain Syndromes (1834–1839)

2:30PM-4:00PM: Abstract Number: 1880

Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)

4M090 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical II: Clinical Trials II (1875–1880)

2:30PM-4:00PM: Abstract Number: 1848

Cardiovascular Risk Factors in Adults with Juvenile Idiopathic Arthritis in Sustained Remission

4M084 ACR Abstract: Pediatric Rheum–Clinical I: Outcomes & Comorbidities (1846–1851)

2:30PM-4:00PM: Abstract Number: 1882

Characteristics and Treatment Outcomes of Takayasu Arteritis in a Nationwide, Retrospective Cohort Study in Japan

4M091 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os I: Population-Based Studies(1881–1886)

2:30PM-4:00PM: Abstract Number: 1884

Clinical Features and Outcome of Patients with Polyarteritis Nodosa – a Global Collaborative Study

4M091 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os I: Population-Based Studies(1881–1886)

2:30PM-4:00PM: Abstract Number: 1841

Current Rheumatology Fellows Experiences with Health Disparities and Disparity Education: A Qualitative Study

4M083 ACR Abstract: Healthcare Disparities in Rheumatology (1840–1845)

2:30PM-4:00PM: Abstract Number: 1845

Defining and Examining Retention in Care in an Urban Lupus Cohort

4M083 ACR Abstract: Healthcare Disparities in Rheumatology (1840–1845)

2:30PM-4:00PM: Abstract Number: 1860

Development and Validation of a Microrna Panel to Differentiate between Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Control Subjects

4M086 ACR Abstract: RA–DX, Manifestations, & Outcomes II: DX & Prognosis I (1858–1863)

2:30PM-4:00PM: Abstract Number: 1835

Diagnosis of Fibromyalgia: Disagreement between Fibromyalgia Criteria and Clinician-Based Fibromyalgia Diagnosis in a University Clinic

4M082 ACR Abstract: Fibromyalgia & Other Clinical Pain Syndromes (1834–1839)

2:30PM-4:00PM: Abstract Number: 1881

Discovery and Validation of Novel Disease Subsets in 806 Patients with Takayasu’s Arteritis across Four International Cohorts

4M091 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os I: Population-Based Studies(1881–1886)

2:30PM-4:00PM: Abstract Number: 1840

Disease Activity in Rheumatoid Arthritis Patients Is Influenced By Countries’ Socioeconomics: Results from the Meteor Registry

4M083 ACR Abstract: Healthcare Disparities in Rheumatology (1840–1845)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].